PDCD1 and colorectal carcinoma: Early studies on combinations of Cetuximab with anti PD-1 Avelumab [1520,1521] or the combination of panitumumab with (anti PD-1 inhibitor) and ipilimumab (anti CTLA-4) in CRC have shown promising response rates [1522].